Pfizer axes sickle cell, beta thalassemia deal with Syros

Pfiz­er ter­mi­nat­ed a deal that Sy­ros Phar­ma­ceu­ti­cals made with Glob­al Blood Ther­a­peu­tics to de­vel­op treat­ments for be­ta tha­lassemia and sick­le cell dis­ease.

Pfiz­er ac­quired GBT last year for $5.4 bil­lion.

Un­der the agree­ment from 2019, GBT had an ex­clu­sive li­cense to de­vel­op and com­mer­cial­ize any com­pounds that re­sult­ed from the Sy­ros col­lab­o­ra­tion. Sy­ros is cur­rent­ly de­vel­op­ing can­di­dates for dif­fer­ent types of can­cer, in­clud­ing myelodys­plas­tic syn­dromes and acute myeloid leukemia.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN